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Osteonecrosis of the jaw (ONJ) is a rare but serious lesion of the jaw, characterized mainly by exposed necrotic bone;
it is  related to various  drugs, usually used for treating patients with advanced malignancies. Drugs implicated in ONJ
are: nitrogen-containing bisphosphonates (NBPs), denosumab,   anti-angiogenic drugs (e.g bevacizumab, sunitinib,
sorafenib) and  the selective mammalian target of rapamycin mTOR,  everolimus. Previous data regarding the  com-
bining of  NBPs  with antiangiogenic agents conflict with some reports  (indicating a similar risk of ONJ compared with
the use of  NBPs  alone1);  other reports show  significantly higher rates (18% vs 1% with  NBPs  alone) of the inci-
dence of ONJ2. The mTOR is a serine/threonine kinase, a component of a complex signaling pathway, involved in cell
growth and metabolism,  reducing  VEGF levels and inhibiting  the growth and proliferation of tumor cells, endothelial
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cells, fibroblasts and blood vassels. Everolimus has been  approved for the treatment of advanced breast cancer, neu-
roendocrine tumors of pancreatic origin (pNET), and advanced renal cell carcinoma (RCC)3. 
This case report may help to explain the temporal relationship between therapy and the occurrence of ONJ with the
sequential use of  NBPs and mTOR.
A 64-year-old male patient underwent a left, radical nephrectomy in 1992 for clear-cell renal carcinoma. In July 2010
he developed a bone metastasis and he was treated with zoledronic acid 4 mg IV every 4 weeks between 7 July
2010 and 17 August 2012. In February 2011 he had another recurrence, a lung metastasis treated with lobectomy
and everolimus 10 mg/die for 6 months from 11 April 2011 to 31 October 2012. In 13 October 2012 the patient
showed a facial enlargement and oral fistula in the first quadrant with no history of tooth extraction. A bone scan re-
vealed an ill-defined radiolucency and an orosinusal communication. In January 2013 the patient  underwent a right
and partial left maxillectomy and is currently being  followed up to minimize the risk of new adverse reactions.
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